NASDAQ
Kodiak Sciences Inc (KOD)
♥ 714 Thanks from members
Kodiak Sciences Inc. exhibits a strongly polarized market sentiment driven by successful late-stage Phase 3 clinical readouts for Zenkuda in diabetic retinopathy, balancing massive valuation gains against looming fundraising needs, dilution risks, and heavy competitive pressures.